Celltrion’s Remsima Logs Record High Sales in U.S. in 2021

SEOUL, Feb. 14 (Korea Bizwire) — Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday. Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to US$385 million in 2021, Celltrion Healthcare said, citing industry data. Remsima references Janssen [...]